The nurse is providing client education for a postmenopausal client; which risks associated with estrogen/progestin therapy should the nurse discuss with the client? (Select all that apply.)
Decreased bone density
Ovarian cancer
Stroke
Increased colon cancer
Deep vein thrombosis
Correct Answer : B,C,E
A) This is not a risk of estrogen/progestin therapy. In fact, estrogen/progestin therapy can help prevent osteoporosis and fractures by increasing bone density and strength.
B) This is a possible risk of estrogen/progestin therapy. Some studies have suggested that taking estrogen/progestin therapy for more than five years may increase the risk of ovarian cancer. However, other studies have not found this association
C) This is a serious risk of estrogen/progestin therapy. Estrogen/progestin therapy can increase the risk of blood clots, which can lead to stroke or heart attack. The risk is higher for women who smoke, have high blood pressure, diabetes, or a history of cardiovascular disease.
D) This is not a risk of estrogen/progestin therapy. In fact, some studies have suggested that estrogen/progestin therapy may reduce the risk of colon cancer by lowering inflammation and promoting regular bowel movements.
E) This is another serious risk of estrogen/progestin therapy. Deep vein thrombosis (DVT) is a condition where a blood clot forms in a deep vein, usually in the leg. It can cause pain, swelling, and redness in the affected area. If the clot breaks off and travels to the lungs, it can cause a life threatening condition called pulmonary embolism (PE). Estrogen/progestin therapy can increase the risk of DVT and PE by making the blood more likely to clot
Nursing Test Bank
Naxlex Comprehensive Predictor Exams
Related Questions
Correct Answer is D
Explanation
a) Increasing the frequency of medication dosing may lead to higher overall exposure and is not necessarily related to hepatic metabolism.
b) Ordering a dose that is higher than an adult dose could result in excessive drug levels, especially in a newborn with immature hepatic function.
c) Discontinuing the drug after one or two treatments may not be necessary if the dose is appropriately adjusted based on hepatic metabolism.
d) Ordering a lower dose is appropriate because hepatic metabolism in newborns is often immature, and lower doses are required to avoid toxicity.
Correct Answer is C
Explanation
a) Insulin glargine is a long-acting basal insulin and is not typically administered before each meal.
b) Administering insulin glargine after meals is not the standard practice. It is given once daily to provide a continuous basal insulin level.
c) Insulin glargine is a once-daily basal insulin that is usually administered at the same time every day to maintain a consistent level of insulin in the body.
d) Unlike short-acting insulins, insulin glargine is not given with meals but provides a basal level of insulin throughout the day.
Whether you are a student looking to ace your exams or a practicing nurse seeking to enhance your expertise , our nursing education contents will empower you with the confidence and competence to make a difference in the lives of patients and become a respected leader in the healthcare field.
Visit Naxlex, invest in your future and unlock endless possibilities with our unparalleled nursing education contents today
Report Wrong Answer on the Current Question
Do you disagree with the answer? If yes, what is your expected answer? Explain.
Kindly be descriptive with the issue you are facing.